Badanie mające na celu sprawdzenie, w jaki sposób różne ilości badanej interwencji o nazwie PF-07832837 są tolerowane i działają w organizmie u zdrowych osób dorosłych i pacjentów.

Kryteria wyłączenia kto nie może wziąć udziału (11)

1. Have a history of systemic infection requiring hospitalization and parenteral antimicrobial therapy, any lymphoproliferative disorder, malignancies.
2. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, immunological/rheumatological disorder.
3. Have undergone significant trauma or major surgery within 1 month of the first dose of study intervention.
4. Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis (TB) as defined by both of the following:
5. A positive QuantiFERON-TB Gold In-tube or equivalent test.
6. History of either untreated or inadequately treated latent or active TB infection, or current treatment for the same. Part 2 Only
7. Currently have active forms of other inflammatory skin diseases
8. Have history of or current evidence of skin conditions at the time of Day 1 that would interfere with evaluation of atopic dermatitis or response to treatment. Have active chronic or acute skin infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks prior to Day 1, or superficial skin infections within 1 week prior to Day 1.
9. Score of ≥ 5 on the Fitzpatrick Skin Type Assessment.
10. History of anaphylaxis with the following exceptions: participants with sensitivity and/or anaphylaxis only to a single, avoidable allergen (eg, aspirin, penicillin, sulfa drugs, nonsteroidal anti-inflammatory drugs [NSAIDs], peanuts) may be enrolled, if in the opinion of the investigator, the participant is aware of the hypersensitivity and avoids the problematic allergen. Participants must carry appropriate treatment for anaphylaxis and must know how to manage anaphylactic reactions.
11. Any investigational or experimental therapy taken or procedure performed for AD, psoriasis, psoriatic arthritis, rheumatoid arthritis or other inflammatory diseases in the previous 1 year should be discussed with the Pfizer Medical Monitor (or designee).